URGN

UroGen Pharma Ltd.

Healthcare · $2.0B market cap

We can't put a fair value on URGN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth-54.9% a year✗

Sales growth23.5% a year✓

Free cash flow growth—?

Return on invested capital-55.3%✗

Follow URGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds URGN. In Q2 2026, 1 opened a position. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$1.1M

29,615 shares

Moves in Q2 2026

New position: Polen Capital Management

Insider activity

Since Sep 7, 2026: no open-market purchases, 2 sales worth $102K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Smith Jason Drew

General Counsel · 2026-09-08

Sold

$65K

Schoenberg Mark

Chief Medical Officer · 2026-09-08

Sold

$37K

Other filings

Smith Jason Drew

General Counsel · 2026-09-07

Option exercise

3,334 shares

Schoenberg Mark

Chief Medical Officer · 2026-09-07

Option exercise

1,667 shares

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a…

Biotechnology